|
Author:
Date:
2021-03-20
[Abstract] The activation of the Takeda G-protein receptor 5 (TGR5, also known as the G protein-coupled bile acid receptor 1, GPBAR1) in enteroendocrine L-cells results in secretion of the anti-diabetic hormone Glucagon-Like Peptide 1 (GLP-1) into systemic circulation. Consequently, recent research has focused on identification and development of TGR5 agonists as type 2 diabetes therapeutics. However, the clinical application of TGR5 agonists has been hampered by side effects of these compounds that primarily result from their absorption into circulation. Here we describe an in vitro screening protocol to evaluate the TGR5 agonism, GLP-1 secretion, and gut-restricted properties of small molecules. The protocol involves differentiating gut epithelial and endocrine cells together in transwells to ...
[摘要] [摘要]肠内分泌L细胞中的Takeda G蛋白受体5（TGR5，也称为G蛋白偶联胆汁酸受体1，GPBAR1）的激活导致抗糖尿病激素胰高血糖素样肽1的分泌。 （GLP-1）进入全身循环。因此，最近的研究集中于鉴定和开发TGR5激动剂作为2型糖尿病治疗剂。但是，TGR5激动剂的临床应用受到这些化合物的副作用的阻碍，这些副作用主要是由于它们吸收进入循环系统所致。这里我们描述一个体外 筛选协议以评估TGR5激动剂，GLP-1分泌和小分子的肠道限制性特性。该协议涉及在跨孔中将肠道上皮细胞和内分泌细胞一起分化，以评估TGR5激动剂的药效学和化合物对肠道单层的毒性。作为概念的证明，我们证明了该协议在评估有效的TGR5激动剂自然存在的胆汁酸代谢物的性质中的应用。该协议改编自Chaudhari等人。（202 1 ）。
[背景和d ] GI道的肠壁是由几个不同类型的细胞，每一个特定的和，有时独有的功能的（阿莱尔等人。，2018） ...
|